Raed A Dweik

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4514179/publications.pdf

Version: 2024-02-01

74 papers	5,019 citations	186265 28 h-index	88630 70 g-index
74 all docs	74 docs citations	74 times ranked	6924 citing authors

#	Article	IF	Citations
1	Impact of Esophageal Pressure Measurement on Pulmonary Hypertension Diagnosis in Patients With Obesity. Chest, 2022, 162, 684-692.	0.8	9
2	Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 14-23.	5.6	32
3	Abnormal levels of apolipoprotein Aâ€Ⅰ in chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-7.	1.7	6
4	Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?. Journal of Heart and Lung Transplantation, 2021, 40, 614-622.	0.6	4
5	The breath print represents a novel biomarker of malnutrition in pulmonary arterial hypertension: a proofâ€ofâ€concept study. Journal of Parenteral and Enteral Nutrition, 2021, 45, 1645-1652.	2.6	2
6	Cutaneous Iontophoresis of Vasoactive Medications in Patients with Sclerodermaâ€•Associated Pulmonary Arterial Hypertension. Microcirculation, 2021, , e12734.	1.8	0
7	Surge capacity and capability of intensive care units across a large healthcare system: An operational blueprint for regional integration. American Journal of Disaster Medicine, 2021, 16, 179-192.	0.3	4
8	Specific O-GlcNAc modification at Ser-615 modulates eNOS function. Redox Biology, 2020, 36, 101625.	9.0	21
9	Breath Metabolomics Provides an Accurate and Noninvasive Approach for Screening Cirrhosis, Primary, and Secondary Liver Tumors. Hepatology Communications, 2020, 4, 1041-1055.	4.3	32
10	Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension. Chest, 2020, 158, 2546-2555.	0.8	11
11	Platelet glycolytic metabolism correlates with hemodynamic severity in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L562-L569.	2.9	11
12	Comparison of volatile organic compound profiles in exhaled breath versus plasma headspace in different diseases. Journal of Breath Research, 2020, 14, 036003.	3.0	5
13	The scientific rationale for the use of simple masks or improvised facial coverings to trap exhaled aerosols and possibly reduce the breathborne spread of COVID-19. Journal of Breath Research, 2020, 14, 030201.	3.0	18
14	A pilot study on the kinetics of metabolites and microvascular cutaneous effects of nitric oxide inhalation in healthy volunteers. PLoS ONE, 2019, 14, e0221777.	2.5	5
15	Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Blood Advances, 2019, 3, 2732-2737.	5.2	9
16	O-GlcNAc Transferase Regulates Angiogenesis in Idiopathic Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2019, 20, 6299.	4.1	19
17	Gasometric gradients between blood obtained from the pulmonary artery wedge and pulmonary artery positions in pulmonary arterial hypertension. Respiratory Research, 2019, 20, 6.	3.6	6
18	Serum Chloride Levels Track With SurvivalÂin Patients With Pulmonary ArterialÂHypertension. Chest, 2018, 154, 541-549.	0.8	24

#	Article	IF	Citations
19	Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension. PLoS ONE, 2018, 13, e0197700.	2.5	14
20	Bariatric surgery in patients with pulmonary hypertension. Surgery for Obesity and Related Diseases, 2018, 14, 1581-1586.	1.2	12
21	Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS ONE, 2018, 13, e0191869.	2.5	17
22	Molecular breath analysis identifies the breathprint of renal failure. Journal of Breath Research, 2017, 11, 026009.	3.0	12
23	Effect of Weight on Parenteral Prostacyclin Analogues Dosing in Pulmonary Hypertension. Chest, 2017, 151, 1189-1192.	0.8	0
24	Pulmonary Hypertension and Precision Medicine through the â€œOmicsâ€•Looking Glass. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1558-1560.	5.6	5
25	Changes in main pulmonary artery diameter during followâ€up have prognostic implications in pulmonary arterial hypertension. Respirology, 2017, 22, 1649-1655.	2.3	19
26	Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?. Pulmonary Circulation, 2017, 7, 727-729.	1.7	4
27	Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. Clinical Cardiology, 2017, 40, 356-363.	1.8	9
28	Assessing the kinetics of microbubble appearance in cirrhotic patients using transthoracic saline contrastâ€enhanced echocardiography. Echocardiography, 2017, 34, 1439-1446.	0.9	14
29	Abnormal Glucose Metabolism and High-Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2017, 14, 190-199.	3.2	36
30	Mitochondrial Haplogroups and Risk of Pulmonary Arterial Hypertension. PLoS ONE, 2016, 11, e0156042.	2.5	23
31	Novel Methods in Pulmonary Hypertension Phenotyping in the Age of Precision Medicine (2015 Grover) Tj ETQq1 1 0.784314 rgBT /O	1.7	11
32	Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 564-575.	2.9	22
33	A Distinct Colon-Derived Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its Complications. Clinical and Translational Gastroenterology, 2016, 7, e201.	2.5	21
34	Portable Breath Monitoring: A New Frontier in Personalized Health Care. Electrochemical Society Interface, 2016, 25, 63-67.	0.4	8
35	Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis. Respiratory Medicine, 2016, 117, 65-72.	2.9	30
36	Pediatric Pulmonary Hypertension. Annals of the American Thoracic Society, 2016, 13, 967-969.	3.2	2

#	Article	IF	Citations
37	Isolation and analysis of sugar nucleotides using solid phase extraction and fluorophore assisted carbohydrate electrophoresis. MethodsX, 2016, 3, 251-260.	1.6	16
38	Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 877-886.	6.1	71
39	What is the best approach to a high systolic pulmonary artery pressure on echocardiography?. Cleveland Clinic Journal of Medicine, 2016, 83, 256-260.	1.3	14
40	Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1014-1016.	5.6	11
41	Heart Rate Recovery is an Important Predictor of Outcomes in Patients with Connective Tissue Diseaseâ€“Associated Pulmonary Hypertension. Pulmonary Circulation, 2015, 5, 565-576.	1.7	20
42	The Rise and Fall of Hyaluronan in Respiratory Diseases. International Journal of Cell Biology, 2015, 2015, 1-15.	2.5	62
43	O -Linked Î²-N-Acetylglucosamine Transferase Directs Cell Proliferation in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2015, 131, 1260-1268.	1.6	48
44	Shot-noise Limited Faraday Rotation Spectroscopy for Detection of Nitric Oxide Isotopes in Breath, Urine and Blood. Scientific Reports, 2015, 5, 9096.	3.3	38
45	Outcomes of Î²-blocker use in pulmonary arterial hypertension: a propensity-matched analysis. European Respiratory Journal, 2015, 46, 750-760.	6.7	43
46	Analysis of breath volatile organic compounds in children with chronic liver disease compared to healthy controls. Journal of Breath Research, 2015, 9, 026002.	3.0	28
47	Isoprene in the Exhaled Breath is a Novel Biomarker for Advanced Fibrosis in Patients with Chronic Liver Disease: A Pilot Study. Clinical and Translational Gastroenterology, 2015, 6, e112.	2.5	79
48	Elevated pulmonary pressure: A novel risk marker in kidney disease?. Kidney International, 2015, 88, 7-9.	5.2	2
49	Modification of Hyaluronan by Heavy Chains of Inter-Î±-Inhibitor in Idiopathic Pulmonary Arterial Hypertension. Journal of Biological Chemistry, 2014, 289, 6791-6798.	3.4	36
50	Breath Analysis in Pulmonary Arterial Hypertension. Chest, 2014, 145, 551-558.	0.8	39
51	Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controls. Physiological Reports, 2014, 2, e12038.	1.7	10
52	Is Pulmonary Hypertension a Metabolic Disease?. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 973-975.	5.6	7
53	Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. European Journal of Gastroenterology and Hepatology, 2014, 26, 82-87.	1.6	82
54	Prognostic Value of Echocardiographic Changes in Patients with Pulmonary Arterial Hypertension Receiving Parenteral Prostacyclin Therapy. Journal of the American Society of Echocardiography, 2014, 27, 733-741.e2.	2.8	27

#	Article	IF	Citations
55	The Breathprints in Patients With Liver Disease Identify Novel Breath Biomarkers in Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2014, 12, 516-523.	4.4	94
56	Why patients who die of worsening pulmonary arterial hypertension are not on parenteral prostacyclin analog treatment?. Journal of Heart and Lung Transplantation, 2014, 33, 221.	0.6	3
57	An Official American Thoracic Society Statement: Pulmonary Hypertension Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 345-355.	5.6	70
58	Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice. International Journal of Clinical and Experimental Pathology, 2014, 7, 1935-46.	0.5	13
59	Single Exhaled Breath Metabolomic Analysis Identifies Unique Breathprint in Patients With Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1463-1464.	2.8	68
60	Clinical Characterization and Survival of Patients with Borderline Elevation in Pulmonary Artery Pressure. Pulmonary Circulation, 2013, 3, 916-925.	1.7	49
61	Response. Chest, 2013, 143, 273-274.	0.8	2
62	Cardiovascular Biomarkers in Exhaled Breath. Progress in Cardiovascular Diseases, 2012, 55, 34-43.	3.1	91
63	Determinants of Exhaled Breath Condensate pH in a Large Population With Asthma. Chest, 2011, 139, 328-336.	0.8	61
64	Update on Pulmonary Vascular Diseases 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 26-31.	5.6	3
65	An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (F<scp>e</scp>_{NO}) for Clinical Applications. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 602-615.	5.6	2,047
66	Strategic Plan for Lung Vascular Research. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1554-1562.	5.6	73
67	Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, at-Risk Phenotype among Patients with Asthma. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1033-1041.	5.6	252
68	Exhaled breath analysis: the new frontier in medical testing. Journal of Breath Research, 2008, 2, 030301.	3.0	83
69	Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1342-1347.	7.1	342
70	Detection of Lung Cancer by Sensor Array Analyses of Exhaled Breath. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1286-1291.	5.6	514
71	Primary pulmonary hypertension: an overview of epidemiology and pathogenesis.. Cleveland Clinic Journal of Medicine, 2003, 70, S2-S2.	1.3	46
72	Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet, The, 2002, 360, 886-887.	13.7	32

#	Article	IF	Citations
73	High Levels of Exhaled Nitric Oxide (NO) and NO Synthase III Expression in Lesional Smooth Muscle in Lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 414-418.	2.9	28
74	Hypertensive Urgency Induced by an Interaction of Mirtazapine and Clonidine. Pharmacotherapy, 2000, 20, 476-478.	2.6	38